Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912520 | 0.84 | MGLL (0.69) | MGLLCHRNA7JAK2JAK1SCN9A | |
| SCHEMBL16564221 | 0.84 | MGLL (0.53) | MGLLCHRNA7JAK2JAK1SCN9A | |
| SCHEMBL142449 | 0.83 | CHRNA7 (0.40) | MGLLMCHR1CHRNA7JAK2JAK1 | |
| SCHEMBL911380 | 0.78 | MGLL (0.67) | MGLLCHRNA7SCN9ASCN10A | |
| SCHEMBL912643 | 0.78 | MGLL (0.67) | MGLLCHRNA7SCN9ASCN10A | |
| SCHEMBL120247 | 0.76 | CHRNA7 (0.47) | MGLLCHRNA7JAK2JAK1 | |
| SCHEMBL122498 | 0.76 | MGLL (0.38) | MGLLCHRNA7JAK2JAK1 | |
| SCHEMBL120252 | 0.76 | CHRNA7 (0.40) | MGLLCHRNA7JAK2JAK1 | |
| SCHEMBL2135736 | 0.76 | MGLL (0.49) | MGLLMCHR1CHRNA7JAK2JAK1 | |
| SCHEMBL694263 | 0.73 | SCN9A (0.49) | MGLLCHRNA7JAK2JAK1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8759533-B2 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759333-B2 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885MCHR1 4236/4885CHRNA7 4634/4885 |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885MCHR1 4236/4885CHRNA7 4634/4885 |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MGLL 4/4885MCHR1 4322/4885CHRNA7 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.